Stage I Pancreatic Cancer
6
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.7%
1 terminated out of 6 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer